Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells

Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. Herein, we indicated for the first time that OSI in...

Full description

Saved in:
Bibliographic Details
Published in:Toxicology and applied pharmacology 2017-04, Vol.321, p.18-26
Main Authors: Tang, Zheng-Hai, Cao, Wen-Xiang, Su, Min-Xia, Chen, Xiuping, Lu, Jin-Jian
Format: Article
Language:English
Subjects:
60 APPLIED LIFE SCIENCES
A549 Cells
Acrylamides
Aniline Compounds
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
APOPTOSIS
Apoptosis - drug effects
Apoptosis - physiology
Autophagy
Autophagy - drug effects
Autophagy - physiology
AZD9291
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - metabolism
CATALASE
Cell Survival - drug effects
Cell Survival - physiology
CYSTEINE
Dose-Response Relationship, Drug
FLUORESCENCE
GROWTH FACTORS
HCT116 Cells
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
LUNGS
MICROTUBULES
MUTATIONS
NEOPLASMS
Osimertinib
PATIENTS
PHOSPHOTRANSFERASES
Piperazines - pharmacology
Piperazines - therapeutic use
PLASMIDS
Reactive Oxygen Species - metabolism
RECEPTORS
ROS
TYROSINE
VITAMIN E
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M mutation. Herein, we indicated for the first time that OSI increased the accumulations of cytoplasmic vacuoles, the expression of phosphatidylethanolamine-modified microtubule-associated protein light-chain 3 (LC3-II), and the formation of GFP-LC3 puncta in various cancer cells. The OSI-induced expression of LC3-II was further increased when combined treatment with chloroquine (CQ), an autophagy inhibitor, and the mRFP-EGFP-LC3 plasmid-transfected cells exposed to OSI led to the production of more red-fluorescent puncta than green-fluorescent puncta, indicating OSI induced autophagic flux in the NSCLC cells. Knockdown of EGFR showed no effect on the OSI-induced expression of LC3-II in NCI-H1975 cells. In addition, OSI increased reactive oxygen species (ROS) generation and scavenge of ROS via pretreatment with N-acetyl-l-cysteine (NAC), catalase (CAT), or vitamin E (Vita E) significantly inhibited OSI-induced the accumulations of cytoplasmic vacuoles, the expression of LC3-II, as well as the formation of GFP-LC3 puncta. Combinative treatment with CQ could not remarkably change the OSI-induced cell viability decrease, whereas the OSI-induced cell viability decrease and apoptosis could be reversed through pretreatment with NAC, CAT, and Vita E, respectively. Taken together, this is the first report that OSI induces an accompanied autophagy and the generation of ROS is critical for the OSI-induced autophagy, cell viability decrease, and apoptosis in NSCLC cells. •Osimertinib induced the expressions of cytoplasmic vacuoles and autophagic markers in different cancer cells.•Osimertinib induced autophagic flux in NSCLC NCI-H1975 and HCC827 cell lines.•ROS generation contributed to osimertinib-induced cytoplasmic vacuoles, autophagy, cell viability decrease, and apoptosis.
ISSN:0041-008X
1096-0333
DOI:10.1016/j.taap.2017.02.017